About Nocionix,Inc.
Nocionix develops autonomic neuromodulation, a therapy for people with chronic pain. The therapy uses no hormones, surgery, or opioids. Nocionix describes it as a new class of therapy.
Nocionix is based in Westlake, Ohio, at 159 Crocker Park Boulevard, Suite 400. Anthony Caparso is its president.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 23, 2026 | Nov 4, 2026 | $2,700,000of $10.0M target | 1 | $2.7M | Debt, Convertible notes and equity issuable upon any conversion thereofRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Nocionix,Inc.
Nocionix develops autonomic neuromodulation, a therapy for chronic pain. The therapy does not rely on hormones, surgery, or opioids. Nocionix is based in Westlake, Ohio. Anthony Caparso is its president.
The problem it targets
Nocionix's view is that chronic pain therapy should reset the pain system, not only the signal. Its homepage gives no further detail on how the therapy works.
We wrote this summary from public statements by Nocionix,Inc. and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Nocionix,Inc.'s Form D filed Nov 4, 2026.